Search Results - "Kulikowski, Ewelina"

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection by Mills, Richard J., Humphrey, Sean J., Fortuna, Patrick R.J., Lor, Mary, Foster, Simon R., Quaife-Ryan, Gregory A., Johnston, Rebecca L., Dumenil, Troy, Bishop, Cameron, Rudraraju, Rajeev, Rawle, Daniel J., Le, Thuy, Zhao, Wei, Lee, Leo, Mackenzie-Kludas, Charley, Mehdiabadi, Neda R., Halliday, Christopher, Gilham, Dean, Fu, Li, Nicholls, Stephen J., Johansson, Jan, Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina, Sokolowski, Kamil A., Tse, Brian W.C., Devilée, Lynn, Voges, Holly K., Reynolds, Liam T., Krumeich, Sophie, Mathieson, Ellen, Abu-Bonsrah, Dad, Karavendzas, Kathy, Griffen, Brendan, Titmarsh, Drew, Elliott, David A., McMahon, James, Suhrbier, Andreas, Subbarao, Kanta, Porrello, Enzo R., Smyth, Mark J., Engwerda, Christian R., MacDonald, Kelli P.A., Bald, Tobias, James, David E., Hudson, James E.

“…Cardiac injury and dysfunction occur in COVID-19 patients and increase the risk of mortality. Causes are ill defined but could be through direct cardiac…”
Get full text

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study by Nicholls, Stephen J, Schwartz, Gregory G, Buhr, Kevin A, Ginsberg, Henry N, Johansson, Jan O, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Toth, Peter P, Wong, Norman, Sweeney, Michael, Ray, Kausik K

“…Patients with diabetes and acute coronary syndrome (ACS) are at high risk for subsequent heart failure. Apabetalone is a selective inhibitor of bromodomain and…”
Get full text

RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease by Jahagirdar, Ravi, Attwell, Sarah, Marusic, Suzana, Bendele, Alison, Shenoy, Narmada, McLure, Kevin G, Gilham, Dean, Norek, Karen, Hansen, Henrik C, Yu, Raymond, Tobin, Jennifer, Wagner, Gregory S, Young, Peter R, Wong, Norman C W, Kulikowski, Ewelina

“…Bromodomain (BD) and extra-terminal domain containing proteins (BET) are chromatin adapters that bind acetylated histone marks via two tandem BDs, BD1 and BD2,…”
Get more information

Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators by Tsujikawa, Laura M., Kharenko, Olesya A., Stotz, Stephanie C., Rakai, Brooke D., Sarsons, Christopher D., Gilham, Dean, Wasiak, Sylwia, Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina

“…Bromodomain and extraterminal proteins (BETs) are more than just epigenetic regulators of transcription. Here we highlight a new role for the BET protein BRD4…”
Get full text

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial by Cummings, Jeffrey, Schwartz, Gregory G, Nicholls, Stephen J, Khan, Aziz, Halliday, Chris, Toth, Peter P, Sweeney, Michael, Johansson, Jan O, Wong, Norman C W, Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Lebioda, Kenneth, Ginsberg, Henry N, Winblad, Bengt, Zetterberg, Henrik, Ray, Kausik K

“…Epigenetic changes may contribute importantly to cognitive decline in late life including Alzheimer's disease (AD) and vascular dementia (VaD). Bromodomain and…”
Get more information

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial by Schwartz, Gregory G, Nicholls, Stephen J, Toth, Peter P, Sweeney, Michael, Halliday, Christopher, Johansson, Jan O, Wong, Norman C W, Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Ginsberg, Henry N, Ray, Kausik K

“…In stable patients with type 2 diabetes (T2D), insulin treatment is associated with elevated risk for major adverse cardiovascular events (MACE). Patients with…”
Get full text

Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease by Kulikowski, Ewelina, Halliday, Christopher, Johansson, Jan, Sweeney, Mike, Lebioda, Kenneth, Wong, Norman, Haarhaus, Mathias, Brandenburg, Vincent, Beddhu, Srinivasan, Tonelli, Marcello, Zoccali, Carmine, Kalantar-Zadeh, Kamyar

“…Background/Aims: The association between serum alkaline phosphatase (ALP) with adverse cardiovascular outcomes, in Chronic Kidney Disease (CKD) patients has…”
Get full text

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro by Gilham, Dean, Smith, Audrey L, Fu, Li, Moore, Dalia Y, Muralidharan, Abenaya, Reid, St Patrick M, Stotz, Stephanie C, Johansson, Jan O, Sweeney, Michael, Wong, Norman C W, Kulikowski, Ewelina, El-Gamal, Dalia

“…Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic…”
Get full text

Apabetalone, a Clinical-Stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells by Sarsons, Christopher D, Gilham, Dean, Tsujikawa, Laura M, Wasiak, Sylwia, Fu, Li, Rakai, Brooke D, Stotz, Stephanie C, Carestia, Agostina, Sweeney, Michael, Kulikowski, Ewelina

“…Facioscapulohumeral dystrophy (FSHD) is a muscle disease caused by inappropriate expression of the double homeobox 4 (DUX4) gene in skeletal muscle, and its…”
Get full text

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment by Gilham, Dean, Wasiak, Sylwia, Rakai, Brooke D, Fu, Li, Tsujikawa, Laura M, Sarsons, Christopher D, Carestia, Agostina, Lebioda, Kenneth, Johansson, Jan O, Sweeney, Michael, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina

“…Epigenetic mechanisms are implicated in transcriptional programs driving chronic kidney disease (CKD). Apabetalone is an orally available inhibitor of…”
Get full text

The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation by Wasiak, Sylwia, Fu, Li, Daze, Emily, Gilham, Dean, Rakai, Brooke D., Stotz, Stephanie C., Tsujikawa, Laura M., Sarsons, Chris D., Studer, Deborah, Rinker, Kristina D., Jahagirdar, Ravi, Wong, Norman C. W., Sweeney, Michael, Johansson, Jan O., Kulikowski, Ewelina

“…Brain vascular inflammation is characterized by endothelial activation and immune cell recruitment to the blood vessel wall, potentially causing a breach in…”
Get full text

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease by Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Fu, Li, Rakai, Brooke D., Stotz, Stephanie C., Halliday, Christopher, Tsujikawa, Laura M., Daze, Emily, Gilham, Dean, Wasiak, Sylwia, Jahagirdar, Ravi

“…Chronic systemic inflammation contributes to cardiovascular disease (CVD) and correlates with the abundance of acute phase response (APR) proteins in the liver…”
Get full text

Benefit of Apabetalone on Plasma Proteins in Renal Disease by Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina

“…Apabetalone, a small molecule inhibitor, targets epigenetic readers termed BET proteins that contribute to gene dysregulation in human disorders. Apabetalone…”
Get full text

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease by Toth, Peter P., Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Szarek, Michael, Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman C.W., Sweeney, Michael, Ray, Kausik K.

“…[Display omitted] Nonalcoholic fatty liver disease (NAFLD) is common among patients with type 2 diabetes mellitus (T2DM) and is associated with increased risk…”
Get full text

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy by Fu, Li, Wasiak, Sylwia, Tsujikawa, Laura M., Rakai, Brooke D., Stotz, Stephanie C., Wong, Norman C. W., Johansson, Jan O., Sweeney, Michael, Mohan, Connie M., Khan, Aneal, Kulikowski, Ewelina

“…Fabry disease (FD) is a rare X‐linked disorder of lipid metabolism, characterized by the accumulation of globotriaosylceramide (Gb3) due to defective the…”
Get full text

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes by Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Norek, Karen, Patel, Reena G., McLure, Kevin G., Young, Peter R., Gordon, Allan, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.

“…Apabetalone (RVX-208) inhibits the interaction between epigenetic regulators known as bromodomain and extraterminal (BET) proteins and acetyl-lysine marks on…”
Get full text

Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases by Kulikowski, Ewelina, Rakai, Brooke D., Wong, Norman C. W.

“…Clinical development of bromodomain and extra‐terminal (BET) protein inhibitors differs from the traditional course of drug development. These drugs are…”
Get full text

EPIGENETIC BET READER INHIBITOR APABETALONE / RVX-208 COUNTERS PROFIBROTIC AND CONTRACTILE ACTIVITY OF CARDIAC FIBROBLASTS WITH POTENTIAL BENEFIT FOR HEART FAILURE by Kulikowski, Ewelina, Wasiak, Sylwia, Tsujikawa, Laura, Fu, Li, Gilham, Dean, Sarsons, Christopher, Sweeney, Michael, Johansson, Jan

Get full text

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial by Ray, Kausik K, Nicholls, Stephen J, Buhr, Kevin A, Ginsberg, Henry N, Johansson, Jan O, Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Toth, Peter P, Wong, Norman, Sweeney, Michael, Schwartz, Gregory G

“…IMPORTANCE: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal…”
Get full text

Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension by Van der Feen, Diederik E, Kurakula, Kondababu, Tremblay, Eve, Boucherat, Olivier, Bossers, Guido P L, Szulcek, Robert, Bourgeois, Alice, Lampron, Marie-Claude, Habbout, Karima, Martineau, Sandra, Paulin, Roxane, Kulikowski, Ewelina, Jahagirdar, Ravi, Schalij, Ingrid, Bogaard, Harm Jan, Bartelds, Beatrijs, Provencher, Steeve, Berger, Rolf M F, Bonnet, Sébastien, Goumans, Marie-José

“…Pulmonary arterial hypertension (PAH) is a degenerative arteriopathy that leads to right ventricular (RV) failure. BRD4 (bromodomain-containing protein 4), a…”
Get full text